{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:34:32Z","timestamp":1790937272200,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.tips.2009.09.003","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T04:21:08Z","timestamp":1255753268000},"page":"610-616","source":"Crossref","is-referenced-by-count":36,"title":["A novel method for determining the inhibitory potential of anti-HIV drugs"],"prefix":"10.1016","volume":"30","author":[{"given":"Lin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Alireza","family":"Rabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Siliciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2009.09.003_bib1","unstructured":"UNAIDS. (2008) Report on the global AIDS epidemic, Joint United Nations Programme on AIDS. http:\/\/www.unaids.org."},{"key":"10.1016\/j.tips.2009.09.003_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.tips.2009.09.003_bib3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2009.09.003_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","article-title":"Decay characteristics of HIV-1-infected compartments during combination therapy","volume":"387","author":"Perelson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.003_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.003_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study","volume":"358","author":"Fellay","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2009.09.003_bib9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrd1151","article-title":"Toxicity of antiretroviral therapy and implications for drug development","volume":"2","author":"Carr","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2009.09.003_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/135965350701200808","article-title":"Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification","volume":"12","author":"Keiser","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tips.2009.09.003_bib11","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1126\/science.2467383","article-title":"HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy","volume":"243","author":"Larder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2009.09.003_bib14","series-title":"2007 Medical Management of HIV Infection","author":"Bartlett","year":"2007"},{"key":"10.1016\/j.tips.2009.09.003_bib15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults","volume":"20","author":"Bartlett","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.tips.2009.09.003_bib16","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/j.tips.2009.09.003_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.15.2.247-277.2002","article-title":"Genotypic testing for human immunodeficiency virus type 1 drug resistance","volume":"15","author":"Shafer","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.tips.2009.09.003_bib18","series-title":"HIV Sequence Compendium 2005","first-page":"80","article-title":"Mutations in Retroviral Genes Associated with Drug Resistance","author":"Clark","year":"2005"},{"key":"10.1016\/j.tips.2009.09.003_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","article-title":"A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs","volume":"42","author":"Hertogs","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2009.09.003_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2009.09.003_bib21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib22","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/bies.10196","article-title":"Mathematical models of HIV pathogenesis and treatment","volume":"24","author":"Wodarz","year":"2002","journal-title":"Bioessays"},{"key":"10.1016\/j.tips.2009.09.003_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.003_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.003_bib25","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.274.5289.985","article-title":"Quantitative image analysis of HIV-1 infection in lymphoid tissue","volume":"274","author":"Haase","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.003_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/jtbi.2002.3055","article-title":"Spatiotemporal dynamics of HIV propagation","volume":"218","author":"Strain","year":"2002","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.tips.2009.09.003_bib27","doi-asserted-by":"crossref","first-page":"19079","DOI":"10.1073\/pnas.0707449104","article-title":"Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.003_bib28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose\u2013response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2009.09.003_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis\u2013Menten type and Hill type equations for reference ligands","volume":"59","author":"Chou","year":"1976","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.tips.2009.09.003_bib30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.246.14.1575","article-title":"The inhibitory quotient. A method for interpreting minimum inhibitory concentration data","volume":"246","author":"Ellner","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2009.09.003_bib31","first-page":"430","article-title":"The inhibitory quotient","volume":"59","author":"Neu","year":"1983","journal-title":"Bull. N. Y. Acad. Med."},{"key":"10.1016\/j.tips.2009.09.003_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/01.qui.0000209910.27997.d9","article-title":"Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response","volume":"41","author":"Winston","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2009.09.003_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(06)70436-4","article-title":"Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy","volume":"6","author":"Morse","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tips.2009.09.003_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COH.0b013e3282fbaaba","article-title":"Inhibitory quotient in HIV pharmacology","volume":"3","author":"la Porte","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2009.09.003_bib35","article-title":"The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves","volume":"40","author":"Hill","year":"1910","journal-title":"J. Physiol."},{"key":"10.1016\/j.tips.2009.09.003_bib36","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e3282f12377","article-title":"Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase","volume":"21","author":"Murray","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.tips.2009.09.003_bib37","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1073\/pnas.0711372105","article-title":"Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle","volume":"105","author":"Sedaghat","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.003_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2009.09.003_bib39","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.282.17.1627","article-title":"Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy","volume":"282","author":"Dornadula","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2009.09.003_bib40","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","article-title":"New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma","volume":"41","author":"Palmer","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.tips.2009.09.003_bib41","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1371\/journal.ppat.0030046","article-title":"ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia","volume":"3","author":"Maldarelli","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2009.09.003_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jama.286.2.196","article-title":"HIV-1 drug resistance profiles in children and adults with viral load of <50 copies\/ml receiving combination therapy","volume":"286","author":"Hermankova","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2009.09.003_bib43","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1128\/JVI.77.3.1659-1665.2003","article-title":"Latency in human immunodeficiency virus type 1 infection: no easy answers","volume":"77","author":"Persaud","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.003_bib44","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/382488","article-title":"Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads","volume":"189","author":"Kieffer","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tips.2009.09.003_bib45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jama.293.7.817","article-title":"Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART","volume":"293","author":"Nettles","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2009.09.003_bib46","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.00591-06","article-title":"Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells","volume":"80","author":"Bailey","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.003_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaci.2008.05.033","article-title":"Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection","volume":"122","author":"Shen","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tips.2009.09.003_bib48","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1073\/pnas.0903107106","article-title":"Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy","volume":"106","author":"Dinoso","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.tips.2009.09.003_bib49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1054-3589(07)56009-6","article-title":"Viral drug resistance and fitness","volume":"56","author":"Quinones-Mateu","year":"2008","journal-title":"Adv. Pharmacol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614709001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614709001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T02:21:41Z","timestamp":1685154101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614709001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0165614709001515"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2009.09.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2889960.2558059","asserted-by":"object"}]},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}